Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT00874406 Recruiting - Colorectal Cancer Clinical Trials

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Start date: January 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.

NCT ID: NCT00868569 Recruiting - Colorectal Cancer Clinical Trials

Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer

Start date: January 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether TAC plus FOLFOX4 or TACE plus folfox4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4 only.

NCT ID: NCT00853684 Recruiting - Clinical trials for Advanced Colorectal Cancer

Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

OXCE
Start date: February 2009
Phase: Phase 2
Study type: Interventional

It is hypothesized that other anti-angiogenic agents such as endostar, may augment the effect of chemotherapy regimens in CRC. Endostar, a recombinant human endostatin which expressed and purified in E. coli, was approved by the SFDA for the treatment of non-small-cell lung cancer in 2005. Ling et al. found that endostar suppressed the VEGF-stimulated proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, and the antiangiogenic effects of endostar were correlated with the VEGF-triggered signaling. (Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer, endostar--a new angiogenesis inhibitor prolonged the overall survival, time to progression and improved response rate. (Wang et al, 2005) Based on these results, the investigators design this phase II clinical trial of oxaliplatin, capecitabine and endostar as first line treatment, to evaluate whether endostar can bring survival benefits to patients with advanced colorectal cancer.

NCT ID: NCT00839111 Recruiting - Clinical trials for Colorectal Neoplasms

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in patients with advanced CRC after failure of oxaliplatin treatment.

NCT ID: NCT00825110 Recruiting - Colorectal Cancer Clinical Trials

SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer

Start date: November 2008
Phase:
Study type: Observational

the principal research objective is to form a database of tissue samples from patients with colorectal (bowel) cancer. The tissue samples that will be used for this research will have already been taken for diagnostic or therapeutic reasons. We will also be asking for consent for a research blood sample. The database will be used to improve our understanding of the molecular genetics and gene expression patterns in colorectal cancer.

NCT ID: NCT00813137 Recruiting - Clinical trials for Colorectal Neoplasms

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer

NCT ID: NCT00797485 Recruiting - Colorectal Cancer Clinical Trials

Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Start date: July 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well giving induction therapy with bevacizumab together with combination chemotherapy with or without capecitabine followed by bevacizumab maintenance therapy in treating patients with metastatic colorectal cancer that cannot be removed by surgery.

NCT ID: NCT00788281 Recruiting - Colorectal Cancer Clinical Trials

A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer

Start date: April 2008
Phase: Phase 2
Study type: Interventional

Laparoscopic surgery has been widely accepted for its minimal invasion and safety. However, whether it has the same survival benefit as the traditional open surgery in Chinese population is still unknown. So we designed this study to evaluate the 3 year disease free survival rate in the laparoscopic group versus the open surgery group.

NCT ID: NCT00777478 Recruiting - Colorectal Cancer Clinical Trials

Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer

sutent-capiri
Start date: December 2008
Phase: Phase 1
Study type: Interventional

The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.

NCT ID: NCT00757965 Recruiting - Colorectal Cancer Clinical Trials

Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom

Start date: February 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility for cancer and interactions between genes and the environment in patients with colorectal cancer.